Market Report -- In Play (SCMP)

November 25, 2009 8:26 AM ET

Article tools

Stocks mentioned in this article: Sucampo Pharmaceuticals Inc (SCMP) Stock Quote, Chart, News, Add to Watchlist
Related topics: Movers

Sucampo Pharma announces Lubiprostone data; says the data analyses demonstrated that lubiprostone achieved a statistically significant response in patients with IBS-C as compared to placebo patients i Co presented additional clinical data for lubiprostone. The data presented reflect additional analyses of already disclosed phase 2 and phase 3 clinical trials of lubiprostone in patients with chronic idiopathic constipation and in patients diagnosed with or reporting irritable bowel syndrome with constipation (IBS-C). Overall, the data analyses demonstrated that, in these trials, lubiprostone achieved a statistically significant response in patients with IBS-C as compared to placebo patients in a variety of symptomatic endpoints; demonstrated long-term efficacy through an overall improvement in constipation severity for up to 12 months in adult patients regardless of age, gender or race; and achieved a significant response among refractory constipation patients as compared to placebo. In this analysis, patients treated with lubiprostone 24 mcg B.I.D. showed statistically significant improvements over placebo patients at all weeks in S.B.M. frequency, abdominal discomfort, stool consistency, straining, constipation severity and abdominal bloating.

Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.